Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging

被引:31
|
作者
Wennberg, Alexandra M. V. [1 ]
Hagen, Clinton E. [1 ]
Edwards, Kelly [1 ,4 ]
Roberts, Rosebud O. [1 ,3 ]
Machulda, Mary M. [2 ]
Knopman, David S. [3 ]
Petersen, Ronald C. [3 ]
Mielke, Michelle M. [1 ,3 ]
机构
[1] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Psychol, Rochester, MN USA
[3] Mayo Clin, Dept Neurol, Rochester, MN USA
[4] St Josephs Mercy Hosp, Ann Arbor, MI USA
基金
美国国家卫生研究院;
关键词
cognition; metformin; type II diabetes; RECORDS-LINKAGE; METFORMIN; VITAMIN-B12; DEMENTIA; MELLITUS; DISEASE; ADULT; NORMS;
D O I
10.1002/gps.4900
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
ObjectiveTo determine the cross-sectional and longitudinal associations between diabetes treatment type and cognitive outcomes among type II diabetics. MethodsWe examined the association between metformin use, as compared to other diabetic treatment (ie, insulin, other oral medications, and diet/exercise) and cognitive test performance and mild cognitive impairment (MCI) diagnosis among 508 cognitively unimpaired at baseline type II diabetics enrolled in the Mayo Clinic Study of Aging. We created propensity scores to adjust for treatment effects. We used multivariate linear and logistic regression models to investigate the cross-sectional association between treatment type and cognitive test z scores, respectively. Mixed effects models and competing risk regression models were used to determine the longitudinal association between treatment type and change in cognitive test z scores and risk of developing incident MCI. ResultsIn linear regression analyses adjusted for age, sex, education, body mass index, APOE epsilon 4, insulin treatment, medical comorbidities, number of medications, duration of diabetes, and propensity score, we did not observe an association between metformin use and cognitive test performance. Additionally, we did not observe an association between metformin use and cognitive test performance over time (median=3.7-year follow-up). Metformin was associated with an increased risk of MCI (subhazard ratio (SHR)=2.75; 95% CI=1.64, 4.63, P<.001). Similarly, other oral medications (SHR=1.96; 95% CI=1.19, 3.25; P=.009) and insulin (SHR=3.17; 95% CI=1.27, 7.92; P=.014) use were also associated with risk of MCI diagnosis. ConclusionsThese findings suggest that metformin use, as compared to management of diabetes with other treatments, is not associated with cognitive test performance. However, metformin was associated with incident MCI diagnosis.
引用
收藏
页码:1114 / 1120
页数:7
相关论文
共 50 条
  • [11] Association between Ambient Illumination and Cognitive Impairment: A Population-Based Study of Older
    Shi, Tieyi
    Chen, Baozhong
    BEHAVIOURAL NEUROLOGY, 2023, 2023
  • [12] Severe Hypoglycemia and Cognitive Decline in Older People With Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study
    Feinkohl, Insa
    Aung, Phyu Phyu
    Keller, Marketa
    Robertson, Christine M.
    Morling, Joanne R.
    McLachlan, Stela
    Deary, Ian J.
    Frier, Brian M.
    Strachan, Mark W. J.
    Price, Jackie F.
    DIABETES CARE, 2014, 37 (02) : 507 - 515
  • [13] Diabetic Retinopathy and Cognitive Decline in Older People With Type 2 Diabetes The Edinburgh Type 2 Diabetes Study
    Ding, Jie
    Strachan, Mark W. J.
    Reynolds, Rebecca M.
    Frier, Brian M.
    Deary, Ian J.
    Fowkes, F. Gerald R.
    Lee, Amanda J.
    McKnight, Janet
    Halpin, Patricia
    Swa, Ken
    Price, Jackie F.
    DIABETES, 2010, 59 (11) : 2883 - 2889
  • [14] Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study
    Lin, E.
    Garmo, Hans
    Van Hemelrijck, Mieke
    Adolfsson, Jan
    Stattin, Par
    Zethelius, Bjorn
    Crawley, Danielle
    BMC CANCER, 2020, 20 (01)
  • [15] Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study
    E. Lin
    Hans Garmo
    Mieke Van Hemelrijck
    Jan Adolfsson
    Pär Stattin
    Björn Zethelius
    Danielle Crawley
    BMC Cancer, 20
  • [16] Association between biomass fuel use and the risk of cognitive impairment among older populations in China: a population-based cohort study
    Min Du
    Liyuan Tao
    Lin Zhu
    Jue Liu
    Environmental Health, 20
  • [17] Association between biomass fuel use and the risk of cognitive impairment among older populations in China: a population-based cohort study
    Du, Min
    Tao, Liyuan
    Zhu, Lin
    Liu, Jue
    ENVIRONMENTAL HEALTH, 2021, 20 (01)
  • [18] Risk factors for cognitive impairment in older people with diabetes: a community-based study
    Xiu, Shuangling
    Liao, Qiuju
    Sun, Lina
    Chan, Piu
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10
  • [19] Type 2 diabetes mellitus contributes to cognitive decline in old age: A longitudinal population-based study
    Hassing, LB
    Grant, MD
    Hofer, SM
    Pedersen, NL
    Nilsson, SE
    Berg, S
    Mcclearn, G
    Johansson, B
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2004, 10 (04) : 599 - 607
  • [20] Type 2 diabetes mellitus, brain atrophy and cognitive decline in older people: a longitudinal study
    Michele L. Callisaya
    Richard Beare
    Chris Moran
    Thanh Phan
    Wei Wang
    Velandai K. Srikanth
    Diabetologia, 2019, 62 : 448 - 458